Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib

doi:10.4254/wjh.v14.i7.1438

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2852)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

154

WORD

HTML

1654

Figures (1-1)

242

Tables (1-5)

240

Sum=2329

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

202

Download

321

Sum=523

Jul 27, 2022 (publication date) through May 24, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Hepatol. Jul 27, 2022; 14(7): 1438-1458
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1438

Table 3 Follow-up and evolutionary events in the included patients of each cohort

	BCLC1cohort	BCLC2cohort	Northern Italy cohort	Naples cohort
Patients, n	82	79	221	69
Follow-up (mo)	18.58 (10.33-34.17)	13.05 (6.64-22.36)	12.73 (6.05-25.88)	9.87 (4.51-18.25)
Treatment duration (mo)	9.06 (4.11-17.46)	5.95 (2.14-13.52)	8.52 (2.56-20.78)	8.06 (3.72-16.97)
Adverse Events
Gastrointestinal (Yes)	35 (42.68)	27 (34.18)	23 (10.41)	38 (55.07)
Dermatologic (Yes)	42 (51.22)	28 (35.44)	32 (14.48)	27 (39.13)
Early Dermatologic (Yes)	33 (40.24)	22 (27.85)	28 (12.67)	25 (36.23)
Performance status deterioration (Yes)	44 (53.66)	46 (58.23)	53 (23.98)	0 (0)
Cardiovascular (Yes)	18 (21.95)	14 (17.72)	16 (7.24)	16 (23.19)
Dermatologic and Cardiovascular simultaneously (Yes)	7 (8.54)	5 (6.33)	0 (0)	10 (14.49)
Other (Yes)	48 (58.54)	34 (43.04)	45 (20.36)	65 (94.2)
Death (Yes)	75 (91.46)	47 (59.49)	180 (81.44)	57 (82.61)
Cause of death
HCC	74 (98.67)	46 (97.87)	118 (65.56)	48 (84.21)
Not HCC related	0 (0)	1 (2.13)	58 (32.22)	9 (15.79)
Others¹	1 (1.33)	0 (0)	4 (2.22)	0 (0)

Descriptive statistics are frequencies (%) or median (IQR: Interquartile range), as appropriate. AE: Adverse events; DAE: Dermatological adverse events; eDAE: early Dermatological adverse events.

¹Other causes of Exitus are: 1 Sudden death, 4 unknown.

Citation: Sapena V, Iavarone M, Boix L, Facchetti F, Guarino M, Sanduzzi Zamparelli M, Granito A, Samper E, Scartozzi M, Corominas J, Marisi G, Díaz A, Casadei-Gardini A, Gramantieri L, Lampertico P, Morisco F, Torres F, Bruix J, Reig M. Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib. World J Hepatol 2022; 14(7): 1438-1458
URL: https://www.wjgnet.com/1948-5182/full/v14/i7/1438.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i7.1438